|
TW201641109A
|
|
Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
|
|
AU2015204770A1
|
|
Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
|
|
KR20150138234A
|
|
Ablative immunotherapy
|
|
US2013189301A1
|
|
Ablative immunotherapy
|
|
TW201410561A
|
|
Automated device for a biologic drug distribution
|
|
TW201346031A
|
|
Methods for handling biological drugs containing living cells
|
|
TW201345547A
|
|
Induction of IL-12 using immunotherapy
|
|
WO2013040196A2
|
|
Automated device for biologic drug distribution
|
|
JP2012176991A
|
|
Allogeneic medical treatment for opportunistic infection
|
|
CN103732247A
|
|
Methods for handling biological drugs containing living cells
|
|
KR20140041517A
|
|
Induction of il-12 using immunotherapy
|
|
BR112013003989A2
|
|
composition comprising cd4 + th1 / killer cells and in vitro method to destroy cancer cells, infected cells or combinations thereof
|
|
KR20180123183A
|
|
Methods and compositions for inhibition of treg cells
|
|
US2011142887A1
|
|
Methods and compositions for liquidation of tumors
|
|
US2008112975A1
|
|
Ablative immunotherapy
|
|
US2008112963A1
|
|
Ablative immunotherapy
|
|
US2007086996A1
|
|
Biodegradable T-cell Activation device
|
|
CA2649290A1
|
|
Allogeneic cell therapy for treatment of opportunistic infection
|
|
IL173239D0
|
|
Composition for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof
|
|
WO2005084276A2
|
|
Cell therapy formulation method and composition
|
